FIELD: medicine.
SUBSTANCE: invention relates to medicine and pharmacology and concerns a means for the treatment of non-alcoholic fatty liver disease (NAFLD). The use of the low molecular weight mimetic NGF hexamethylenediamide (bis-L-monosuccinyl-L-glutamyl-L-lysine) as a treatment for NAFLD has been proposed. In an experimental model of NAFLD caused by a high-fat diet in Wistar rats, hexamethylenediamide (bis-N-monosuccinyl-L-glutamyl-L-lysine) at a dose of 5 mg/kg orally eliminates morphological disorders in the liver characteristic of NAFLD. Hexamethylenediamide (bis-N-monosuccinyl-L-glutamyl-L-lysine) reduces abdominal obesity, reduces cholesterol in the blood by 30%, triglycerides by 28% in comparison with animals on a fat diet, but not treated.
EFFECT: expansion of the arsenal of medicines for the treatment of NAFLD, obtaining a more effective, safe, non-toxic drug, suitable for oral use.
1 cl, 4 tbl, 1 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION OF NEUROPROTECTIVE ACTION FOR PARENTERAL APPLICATION ON BASIS OF HEXAMETHYLENEDIAMINE BIS-(N-MONOSUCCINYL-L-GLUTAMIL-L-LYSINE) IN LYOPHILIZED DOSAGE FORM | 2017 |
|
RU2678203C2 |
| PHARMACEUTICAL COMPOSITION OF NEUROPROTECTIVE ACTION FOR ORAL ADMINISTRATION BASED ON HEXAMETHYLENE AMIDE BIS-(N-MONOSUCCINYL-1-GLUTAMYL-L-LYSINE) (VERSIONS), MADE IN FORM OF A TABLET DISPERSIBLE IN THE ORAL CAVITY | 2018 |
|
RU2740754C1 |
| SMALL MOLECULES WITH NGF-LIKE ACTIVITY AND ANTIDIABETIC PROPERTIES | 2013 |
|
RU2613314C2 |
| SUBSTANCE WITH ANGIOGENIC ACTIVITY | 2013 |
|
RU2613184C2 |
| DIMERIC DIPEPTIDE MIMETICS OF NEUROTROFIN-3 | 2022 |
|
RU2800369C1 |
| PHARMACEUTICAL COMPOSITION BASED ON BIS-(N-MONOSUCCINYL-L-SERYL-L-LYSINE) HEXAMETHYLENEDIAMIDE (GSB-106) | 2018 |
|
RU2697254C1 |
| LOW-MOLECULAR MIMETIC BDNF AS AN AGENT FOR TREATING OPIOID DEPENDENCE | 2019 |
|
RU2707301C1 |
| LOW-MOLECULAR NEUROTROPHIN-3 MIMETIC AS AGENT FOR REDUCING PAIN RESPONSE AND RESTORING SENSITIVITY IN PERIPHERAL NEUROPATHY | 2024 |
|
RU2828668C1 |
| DIMERIC DIPEPTIDE MIMETIC BDNF AS AGENT FOR TREATING AND PREVENTING OPIOID ADDICTION | 2023 |
|
RU2823374C1 |
| USING LACTITOL AND AN ORAL DOSAGE FORM FOR TREATING AND PREVENTING NON-ALCOHOLIC FATTY LIVER DISEASE | 2018 |
|
RU2692243C1 |
